[ad_1]
So far, the company is submitting the data to regulators in the United States, Europe and the United Kingdom for an emergency license and hopes to start the approval process around the world.
Some of the more than 50 vaccines in development against COVID-19 have made major news headlines in recent weeks for their promising initial results. Pfizer, Sputnik V and Moderna have been the first to appear to offer a solution to this pandemic. Recently, the final results of the Moderna vaccine trials confirmed that it is 94% effective and that, to date, no one who has been vaccinated with any of its doses has developed a serious disease. (Read: What can we expect from the first vaccines against covid-19, in nine questions)
After confirming the high efficacy that the vaccine can develop, the company will begin the approval process with regulators around the world, a process that the US company has already started by sending data to regulators in the United States, Europe and the United Kingdom for obtain an emergency license.
In a statement, he said he is waiting for the United States Food and Drug Administration (FDA) to consider this issue of an emergency license on December 17, at the meeting they stipulated. Despite the fact that the US company has already signed agreements with several countries, the United States will have access first.
Moderna assured that it hopes to have 20 million doses of its vaccine ready for use in this country by the end of 2020. In addition, he added, it is on track to manufacture 500 million to one billion doses worldwide in 2021. (You can read: Under what conditions will the first doses of the vaccine against COVID-19 arrive in Colombia?)
There are currently more than 50 COVID-19 vaccines in development and already being tested in humans. However, only a few of them have reached phase III of the clinical trial, which implies evaluating their efficacy and safety with a large number of volunteers. In Moderna’s case, for this phase of the study the trials included large numbers of people in the highest risk groups, with 7,000 older than 65 years and more than 5,000 younger people with chronic diseases, such as diabetes, severe obesity, and heart disease .
According to Moderna, there were no serious side effects in the trial volunteers. The most common include arm pain, headaches, and fatigue. Although full trial data has not been published, the company said it will be published in a peer-reviewed journal. Stéphane Bancel, CEO of Moderna, told The Guardian that “this positive primary analysis confirms the ability of our vaccine to prevent Covid-19 disease with an efficacy of 94.1% and, more importantly, the ability to prevent serious disease ”.
To develop the vaccine, Moderna used a new mRNA technology that involves the genetic code of the virus rather than any dead or weakened parts of it. A method also used by Pfizer / BioNTech. (You may be interested: Vaccine against COVID-19 will be free for all Colombians)
[ad_2]
